mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin has been researched along with sepiapterin in 1 studies
| Studies (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Trials (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Recent Studies (post-2010) (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Studies (sepiapterin) | Trials (sepiapterin) | Recent Studies (post-2010) (sepiapterin) |
|---|---|---|---|---|---|
| 69 | 0 | 42 | 207 | 3 | 63 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Champion, HC; Dugas, TR; Duranski, MR; Elrod, JW; Greer, JJ; Kevil, CG; Langston, W; Lefer, DJ; Tao, L | 1 |
1 other study(ies) available for mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and sepiapterin
| Article | Year |
|---|---|
eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling.
Topics: Animals; Biological Availability; Biopterins; Diabetes Mellitus, Type 2; Drug Synergism; Genetic Therapy; Liver; Metalloporphyrins; Mice; Mice, Inbred Strains; Mice, Transgenic; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Nitrites; Phenotype; Phosphorylation; Pterins; Reperfusion Injury; Severity of Illness Index; Tyrosine | 2006 |